Biolyst › ABVXCash & investments
EUR 538M
Abivax S.A. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease on December 15, 2026. There are 2 upcoming events on record.
Cash runway is approximately 69.5 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Across 19 concluded trials, 89% reached completion rather than being terminated or withdrawn.
Track ABVX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ABVX in the tracker
Recent history
Date Event Type Phase
September 21, 2026
6-K filed: Foreign issuer report Filing
—
September 15, 2026
Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation Trial Milestone
Phase 1
July 2, 2026
6-K filed: Foreign issuer report Filing
—
June 29, 2026
6-K filed: Foreign issuer report Filing
—
June 2, 2026
6-K filed: Foreign issuer report Filing
—
May 22, 2026
6-K filed: Foreign issuer report Filing
—
May 20, 2026
6-K filed: Foreign issuer report Filing
—
May 7, 2026
6-K filed: Foreign issuer report Filing
—
April 28, 2026
ABTECT - Maintenance Trial Milestone
Phase 3
April 20, 2026
6-K filed: Foreign issuer report Filing
—
March 23, 2026
6-K filed: Foreign issuer report Filing
—
March 23, 2026
Results filed (20-F) Earnings
—
February 23, 2026
6-K filed: Foreign issuer report Filing
—
December 15, 2025
6-K filed: Foreign issuer report Filing
—
September 8, 2025
6-K filed: Foreign issuer report Filing
—
July 24, 2025
6-K filed: Foreign issuer report Filing
—
July 22, 2025
6-K filed: Foreign issuer report Filing
—
June 24, 2025
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 Trial Milestone
Phase 3
June 24, 2025
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 Trial Milestone
Phase 3
June 11, 2025
6-K filed: Foreign issuer report Filing
—
June 2, 2025
6-K filed: Foreign issuer report Filing
—
April 29, 2025
6-K filed: Foreign issuer report Filing
—
April 22, 2025
6-K filed: Foreign issuer report Filing
—
February 23, 2023
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis Trial Milestone
Phase 2
January 23, 2023
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis Trial Milestone
Phase 2
July 12, 2022
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis Trial Milestone
Phase 2
April 14, 2022
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma Trial Milestone
Phase 1/Phase 2
February 18, 2022
Safety and Pharmacokinetics Study in Healthy Japanese Volunteers Trial Milestone
Phase 1
May 18, 2021
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 Trial Milestone
Phase 1
April 27, 2021
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis Trial Milestone
Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.